Repligen enters the second half of 2026 with a notable split in the data: the stock has rallied 5% on the week to $121.13, yet short interest remains elevated at roughly 10.4% of the free float — and the Street is still pricing in nearly 50% upside from current levels.
Short sellers are a meaningful presence here, but the direction of travel is slightly in their favour for now. Short interest has drifted down from around 10.7% of float in late May to 10.4% today — a modest easing rather than a capitulation. The move follows a sharp rise across May when short positioning climbed from roughly 9.8% to 10.7% before pulling back. The borrow market tells a relaxed story: cost to borrow is running at just 0.45%, one of the lowest readings of the past six weeks, after touching around 0.63% in early May. Availability is more than ample, with over 527% of current short interest available to lend — far above the 52-week trough of 313% seen in mid-May. The lending market is loose, not stressed.
Options positioning is similarly muted. The put/call ratio has nudged up to just above 1.0 — fractionally above its 20-day average of 0.98 — representing a z-score of barely 0.2. That reading is well within normal, nowhere near the hedging demand that would signal genuine concern. The options market is not leaning either way with any conviction.
The Street remains constructively positioned despite a wave of target-price reductions. The consensus is still heavily bullish, with the ORTEX analyst recommendation factor ranked in the 91st percentile. Multiple firms have trimmed targets in recent weeks — JP Morgan cut to $165 from $180, HSBC (in a note filed today) lowered to $150 from $170, and Evercore ISI moved to $140 from $170 — but all maintained positive ratings. Wolfe Research assumed coverage this week at Outperform with a $145 target, and RBC Capital reinstated at $160. The direction is one of target compression, not rating downgrades. The mean analyst price target of $177 implies roughly 46% upside from Tuesday's close, though the gap between current price and consensus is worth flagging: several of the more recent targets cluster between $145 and $165, suggesting the headline mean may still be anchoring on earlier, pre-correction estimates. EPS momentum ranks strongly at the 69th–70th percentile across 30- and 90-day windows, while EV/EBITDA has compressed modestly over the past month to around 36.6x — still a premium multiple reflecting the bioprocessing sector's structural growth narrative.
The institutional roster is long-biased and actively managed. T. Rowe Price leads with just over 11% of shares, adding nearly 1 million shares in Q1. BlackRock added around 240,000 shares through April. Several newer names — Maverick Capital, Wasatch Advisors, and Vanguard Capital Management — appear as fresh positions in the Q1 filings, adding to the picture of active accumulation at lower levels. Insider activity is less informative: the CEO sold just over $536,000 worth of stock in late April, and the executive chairman sold roughly $1.2 million in early March. These are modest in size and consistent with routine plan-driven disposals; trade significance scores are low.
Peer performance on the week is instructive. TMO rose over 7.5% on the week while A (Agilent) surged more than 17%. CRL (Charles River) gained nearly 11.5%. Repligen's 5% weekly gain looks restrained against that backdrop, suggesting the stock has been slower to participate in the sector's bounce even as shorts have started to ease back. The next scheduled earnings event is July 30 — the Q2 print — and the Q1 result in May produced a single-day decline of nearly 4%, though the stock recovered 5.9% over the following week. That post-earnings pattern — a sharp initial selloff giving way to recovery — is the dynamic worth tracking as July approaches.
See the live data behind this article on ORTEX.
Open RGEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
